Literature DB >> 17266089

A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis.

Helena Marzo-Ortega1, Michael J Green, Anne-Maree Keenan, Richard J Wakefield, Susanna Proudman, Paul Emery.   

Abstract

OBJECTIVE: To determine the outcome after 52 weeks of early intervention with intraarticular corticosteroid injections followed by sulfasalazine versus conservative therapy in patients with recent-onset oligoarthritis in a randomized controlled trial.
METHODS: Patients with <or=4 joints with clinical synovitis (disease duration <or=12 months) were randomized to early intervention (EI) with intraarticular methylprednisolone into all synovitic joints or to conservative treatment (CT) with nonsteroidal antiinflammatory drugs alone. Sulfasalazine was administered in both groups for persistent disease or disease that evolved into a polyarthritis. Primary outcome was complete response (CR) defined as the absence of synovitis at 52 weeks. Secondary outcomes included CR at weeks 4 and 12, function (Health Assessment Questionnaire), pain (0-100-mm visual analog scale), and work status.
RESULTS: Fifty-nine patients (34 men, 25 women; mean age 32.9 years; median early morning stiffness 30 minutes) were randomized. At baseline, two-thirds reported that they were work impaired. At 52 weeks, 81% of patients in the EI group achieved CR compared with 57% in the CT group (chi(2) = 3.833, 1 df, P = 0.05). In addition, 45% of patients in the EI group received sulfasalazine as opposed to 14% in the CT group (chi(2) = 5.156, 1 df, P = 0.019). There were no differences in physical disability or work impairment between the treatment groups.
CONCLUSION: Oligoarthritis has a significant impact on function and work ability. Patients treated with EI using intraarticular corticosteroids followed by sulfasalazine therapy if resistant demonstrated reduced synovitis 12 months after treatment compared with those initially treated with more conservative therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266089     DOI: 10.1002/art.22467

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  [Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

Authors:  I H Tarner; K Albrecht; M Fleck; E Gromnica-Ihle; G Keyßer; L Köhler; I Kötter; K Krüger; J Kuipers; H Nüßlein; A Rubbert-Roth; J Wollenhaupt; M Schneider; B Manger; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

2.  Update on the treatment of peripheral arthritis in psoriatic arthritis.

Authors:  Enrique R Soriano; Javier Rosa
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 3.  Clinical approaches to early inflammatory arthritis.

Authors:  Dirkjan van Schaardenburg; Ben A C Dijkmans
Journal:  Nat Rev Rheumatol       Date:  2009-09-29       Impact factor: 20.543

4.  Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial.

Authors:  Izhar C van Eijk; Markus M J Nielen; Irene van der Horst-Bruinsma; Gerard J Tijhuis; Maarten Boers; Ben A C Dijkmans; Dirkjan van Schaardenburg
Journal:  Rheumatology (Oxford)       Date:  2011-12-13       Impact factor: 7.580

Review 5.  Peripheral spondyloarthritis: a neglected entity-state of the art.

Authors:  Philippe Carron; Ann-Sophie De Craemer; Filip Van den Bosch
Journal:  RMD Open       Date:  2020-05

6.  Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design.

Authors:  Ines Rombach; William Tillett; Deepak Jadon; Laura Tucker; Marion Watson; Anne Francis; Yvonne Sinomati; Lucy Eldridge; Melina Dritsaki; Susan J Dutton; Hussein Al-Mossawi; Nicola Gullick; Ben Thompson; Laura C Coates
Journal:  Trials       Date:  2021-03-04       Impact factor: 2.279

7.  Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study.

Authors:  Ines Rombach; Laura Tucker; William Tillett; Deepak Jadon; Marion Watson; Anne Francis; Yvonne Sinomati; Susan J Dutton; Laura C Coates
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-01-10       Impact factor: 3.625

8.  Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in Patients with Peripheral Spondyloarthritis.

Authors:  Grigorios T Sakellariou; Athanasios D Anastasilakis; Ilias Bisbinas; Anastasios Gketsos; Charalampos Berberidis
Journal:  ISRN Rheumatol       Date:  2013-06-11

9.  Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).

Authors:  Lotte Heimans; Gülşah Akdemir; Kirsten V C Wevers-de Boer; Yvonne P Goekoop-Ruiterman; Esmeralda T Molenaar; Johannes H L M van Groenendael; Andreas J Peeters; Gerda M Steup-Beekman; Leroy R Lard; Peter B J de Sonnaville; Bernard A M Grillet; Tom W J Huizinga; Cornelia F Allaart
Journal:  Arthritis Res Ther       Date:  2016-01-21       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.